the third enzyme in the haem biosynthetic pathway, porphobilinogen deaminase, and the accumulation of the porphyrin precursors, 8-aminolevulinic acid and porphobilinogen (fig 1) .1 -5 The clinical onset of the disease usually occurs during or after puberty and is characterised by intermittent attacks of neurological dysfunction, including abdominal pain and other gastrointestinal complaints, hypertension, tachycardia, and various peripheral and central nervous system manifestations. The acute attacks are precipitated by environmental factorsfor example, certain drugs, various hormones and steroids, infections, and starvation-which induce hepatic 8-aminolevulinic acid synthase activity, resulting in the increased production and accumulation of 8-aminolevulinic acid and porphobilinogen and the precipitation of acute symptoms of disease. Normally the excess porphobilinogen would be converted by porphobilinogen deaminase into the porphyrins uroporphyrinogens I and III (fig 1) .6 7The half normal hepatic porphobilinogen deaminase activity in patients with acute intermittent porphyria, however, is insufficient to prevent the pathological accumulation of this porphyrin precursor.
Recent studies have focused attention on the nature of the enzymatic defect in this hepatic porphyria. The physicokinetic properties of porphobilinogen deaminase in erythrocytes from patients with acute intermittent porphyria and normal subjects have been characterised,6 8 and the structural gene encoding the monomeric enzyme and the mutations of the disease has been localised to the distal long arm of chromosome 11. 9 Anderson et al produced monospecific polyclonal antibodies against human porphobilinogen deaminase and used immunological techniques to characterise the defective enzyme in 22 unrelated families with acute intermittent porphyria.8 Two major classes of enzyme defects were identified from the amount of immunologically cross reacting enzyme protein (CRIM) in erythrocyte lysates of acute intermittent porphyria: one class (designated CRIM negative) in which the amount of CRIM was proportional to the enzymatic activity, and a second class (designated CRIM positive) in which non-catalytic, mutant enzyme protein was present. The CRIM positive patients had ratios of CRIM to activity of about 1-6, showing the presence of non-catalytic enzyme protein produced by the 505 mutant porphobilinogen deaminase allele. A more recent study identified a second and unusual CRIM positive mutation in which the amount of non-catalytic, mutant enzyme protein was greater (ratio _ 5-6) than that expected for a single mutant allele (ratio=2-0). Characterisation of this CRIM positive mutation showed that the mutant enzyme was stabilised by bound substrate, which protected it from intraerythrocytic proteolysis."n In Finland over 150 patients with acute intermittent porphyria were identified in a nationwide survey of porphyrias,"' and a large kindred with acute intermittent porphyria was discovered in which the erythrocyte porphobilinogen deaminase activity was normal. ' Results Figure 2 shows the four major mutant types of porphobilinogen deaminase that were distinguished when equal amounts of erythrocyte lysate activity from the 68 patients with acute intermittent porphyria and from normal subjects were subjected to rocket immunoelectrophoresis. The Within each family the data for rocket immunoelectrophoresis and immunotitration for affected relatives were essentially identical. 
Discussion
Four different types of porphobilinogen deaminase mutations were identified by immunological and enzymatic characterisation of the erythrocyte enzyme in patients with acute intermittent porphyria from 33 unrelated families in Finland. These studies showed two CRIM positive10 and two CRIM negative mutations. The CRIM negative mutations were subclassified into two types based on the presence of half normal or normal porphobilinogen deaminase activity in erythrocytes from affected subjects. Within families the enzymatic and immunological properties of erythrocyte porphobilinogen deaminase in each affected relative were the same, consistent with the existence of at least four different, dominantly inherited mutations and the occurrence of genetic heterogeneity at the locus for porphobilinogen deaminase.
Almost 80% of the families studied (including the Skolt Lappish family) were CRIM negative, which indicated that non-catalytic porphobilinogen deaminase protein encoded by the mutant allele was not immunologically detectable in the erythrocyte lysates. The possible molecular lesions responsible for CRIM negative mutations include complete or partial gene deletions as well as point mutations or insertions that alter the processing or stability of mRNA, create chain terminating codons, or appreciably alter the conformation or stability of the mutant protein. The CRIM negative mutations are probably heterogenous at the molecular level, and therefore further characterisation will require the use of appropriate cDNA and genomic probes for the porphobilinogen deaminase structural gene analogous to the elucidation of the molecular defects in the P'-thalassaemias.'l The previously reported family with acute intermittent porphyria with normal erythrocyte porphobilinogen deaminase activity was also classified as CRIM negative (ratio of CRIM to activity=1 0). The clinical manifestations as well as the urinary and faecal excretion of haem precursors and porphyrins in affected members of this family were similar to those observed in patients with acute intermittent porphyria with half normal porphobilinogen deaminase activity. In addition, the results of a provocative oral loading test of 3-aminolevulinic acid were consistent with a defect in porphobilinogen metabolism."3 17 Moreover, the activities of five other haem biosynthetic enzymes were normal. These findings were not limited to this Finnish family, as American and other European kindreds with acute intermittent porphyria with normal porphobilinogen deaminase activities have been identified" (M Doss, personal communication). The nature of the CRIM negative mutations in these families remains unknown. Hepatic and erythrocytic porphobilinogen deaminase isozymes are unlikely to exist under separate genetic control as the enzyme deficiency has been shown in both sources in the same patients with acute intermittent porphyria6 6 9 and the enzyme activities in erythrocytes and liver are immunologically identical.'0 Thus further characterisation of the genetic defect in this kindred with acute intermittent porphyria will also require molecular genetic techniques to determine whether the porphobilinogen deaminase structural gene is intact or whether other, undefined mechanisms are responsible for the acute attacks in these patients.
The two CRIM positive defects presumably represent different point mutations in the structural gene for porphobilinogen deaminase. Previous studies of the non-catalytic enzyme protein from a CRIM positive type 1 family indicated that this mutation resulted in a kineticallv defective enzyme with a slightly decreased stability.8 Immunological investigation of the non-catalytic porphobilinogen deaminase in the CRIM positive type 2 families showed an unusual mutation-that is, the levels of immunoreactive, non-catalytic porphobilinogen deaminase were considerably greater than the maximal theoretical ratio of CRIM to activity of 2 0 for a single mutant allele. Another study has shown that the non-catalytic enzyme protein was bound to substrate,'0 presumably owing to a mutation that increased substrate binding or prevented product release, or both. The mutant enzyme bound to substrate was more resistant to intraerythrocyte proteolysis than the normal enzyme protein, thereby increasing the ratio of CRIM to activity with erythrocyte age. It is intriguing to speculate that if the "super stable" mutant enzyme retained even a fraction of normal activity then the residual activities in erythrocytes and liver would be slightly greater than those in CRIM negative type 1 and CRIM positive type 1 patients and could result in a clinically milder disorder. The mean porphobilinogen deaminase activities in erythrocyte lysates from CRIM negative type 1 and CRIM positive type 1 and type 2 patients support this hypothesis (see table I 2 Characterisation of porphobilinogen deaminase activity in erythrocytes from families with acute intermittent porphyria in Finland provided information concerning the frequency of the various mutations in this fairly homogenous population.'9 Of the 33 families studied, 25 were CRIM negative type 1. Of the seven CRIM positive families, four (120, of all families studied) were CRIM positive type 1 and three (9%' ) were CRIM positive type 2. For comparison, the frequencies of CRIM negative type 1 and 2 and CRIM positive type 1 and 2 mutations in a larger, random sample composed of North and South American patients from various ethnic and demographic ancestries were 90, 3, 2, and 5% respectively.'0 Thus this study documents the molecular genetic heterogeneity of the mutations causing acute intermittent porphyria, even in the fairly homogenous population of Finland.
